Literature DB >> 7470391

Effect of oxymetholone on human cyclic haematopoiesis.

K J Roozendaal, K A Dicke, M L Boonzajer Flaes.   

Abstract

A 62-year-old woman had recurrent fluctuations of neutrophil, monocyte, reticulocyte and platelet counts with a cycling time of 38.5 d. Periodic fluctuations of granulo-, erythro- and megakaryopoiesis were also demonstrated in her bone-marrow. Oxymetholone reduced the magnitude of the profound cyclic fluctuations in all these cell lines. During treatment a reduced number of in vitro CFU-C of the progenitor myeloid series from the bone marrow was observed. Using the patient leucocytes as feeders for normal control marrow cells, indication was found for a fluctuation in colony stimulating activity in vitro, rising above normal at the nadir of the WBC.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7470391     DOI: 10.1111/j.1365-2141.1981.tb02778.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia.

Authors:  D C Dale; M A Bonilla; M W Davis; A M Nakanishi; W P Hammond; J Kurtzberg; W Wang; A Jakubowski; E Winton; P Lalezari
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

2.  The effect of recombinant granulocyte colony-stimulating factor on oral and periodontal manifestations in a patient with cyclic neutropenia: a case report.

Authors:  Sergio Matarasso; Vincenzo Daniele; Vincenzo Iorio Siciliano; Michele D Mignogna; Gianmaria Andreuccetti; Carlo Cafiero
Journal:  Int J Dent       Date:  2010-02-18

3.  Steroid responsive cyclical neutropenia.

Authors:  G A Young; H J Iland; S F Deveridge; P R Forrest; P C Vincent
Journal:  Blut       Date:  1984-03

4.  Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor.

Authors:  Roger M Lyons; Sharon T Wilks; Shelby Young; Gail L Brown
Journal:  J Hematol Oncol       Date:  2011-11-02       Impact factor: 17.388

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.